Atlas Trials

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Clinical trial NCT07505186 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07505186
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell CarcinomaNeoadjuvant Therapy
Start date
2026-05-01
Primary completion
2028-12-31
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.